hero section gradient
12 handpicked stocks

Sovereign-Cloud Specialists

These carefully selected stocks represent companies that keep sensitive digital data within national borders. As governments worldwide tighten regulations on data security, these specialized cloud providers are positioned to thrive in an increasingly data-nationalist world.

Author avatar

Han Tan | Market Analyst

Published on June 17

Your Basket's Financial Footprint

Interpretation of market capitalisation breakdown for the Sovereign-Cloud Specialists basket.

Key Takeaways for Investors:
  • Large-cap dominance suggests generally lower volatility and more stable performance, tending to track broader market movements.
  • Suitable as a core holding rather than a speculative position; consider for long-term allocation within a diversified portfolio.
  • Likely to offer steadier, long-term value rather than rapid, explosive gains; growth expectations should be moderate.
Total Market Cap
  • NET: $74.22B

  • KC: $3.88B

  • SNOW: $83.86B

  • Other

About This Group of Stocks

1

Our Expert Thinking

We're witnessing a major shift toward "data nationalism," where countries require sensitive information to stay within their borders. These companies offer cloud services that comply with strict national regulations, creating a protected market that even tech giants can't easily enter.

2

What You Need to Know

This collection includes both regional cloud providers and companies that build the infrastructure making sovereign clouds possible. They operate in a specialized niche where compliance with local laws creates a competitive advantage against global players.

3

Why These Stocks

These companies were selected because they directly benefit from increasing government mandates for in-country data storage. As digital nationalism rises globally, these specialists are positioned to capture growing demand for locally-compliant cloud services.

Why You'll Want to Watch These Stocks

🌐

Digital Borders Are Rising

As countries enact stricter data residency laws, these companies are uniquely positioned to benefit from the fragmentation of the global internet into nation-specific clouds.

🛡️

Protected Market Opportunity

These specialists operate in regulatory-created markets where even big tech giants must partner with local providers, creating a competitive moat that shelters their business.

🚀

Just Getting Started

The sovereign cloud market is still in its early stages, with new data privacy laws being enacted worldwide that will expand the addressable market for these companies.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions